Bahman Omrani, DO
Internal Medicine · Encino, CANPI 1700945417
Payments from drug & device makers
Across 42 payments — averaging $94.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$2K
- Indivior Inc.$934
- Micromed Inc$387
- Braeburn Inc.$177
- SPR Therapeutics, Inc$150
- Biodelivery Sciences International, Inc.$130
- plus $229 from 4 others
What the payments were for
- Travel & lodging$38710%
- Food & beverage$1,71143%
- Education$1,85647%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 4 | $1,948 |
| Indivior Inc. | 21 | $934 |
| Micromed Inc | 2 | $387 |
| Braeburn Inc. | 2 | $177 |
| SPR Therapeutics, Inc | 1 | $150 |
| Biodelivery Sciences International, Inc. | 1 | $130 |
| Bausch Health US, LLC | 5 | $93 |
| Alkermes, Inc. | 3 | $71 |
| Abbott | 2 | $43 |
| Titan Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUBLOCADE$477
- SPRINT PNS System$150
- BRIXADI$139
- BELBUCA$130
How this compares
$3,954 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 21 | $21,053 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 60 | $9,176 |
| Mesalamine | 12 | $7,180 |
| Buprenorphine Hcl | 15 | $247 |
| Metformin Hcl | 14 | $85 |
| Atenolol-ChlorthalidoneAtenolol/Chlorthalidone | 12 | $55 |
| Gabapentin | 17 | $49 |
| Potassium Chloride | 13 | $26 |
| Ibandronate Sodium | 11 | $25 |
| Diazepam | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Encino
- Tooraj RaoofEncino$6.9M
- Shahram JacobsEncino$4.7M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.